保留皮肤的乳腺癌改良根治术后即刻乳房再造的临床应用

目的探讨保留皮肤的乳腺癌改良根治术后即刻再造乳房的适应证、方法、效果及可行性。方法2002年1月至2007年11月本院对94例乳腺癌患者行保留乳房皮肤皮下乳腺组织切除加腋窝淋巴结清扫术后，应用下腹部横行腹直肌肌皮瓣（transverse rectus abdominis myocutaneous flap，TRAM）、背阔肌肌皮瓣（latissimus dorsi myocutaneous flap，LDM）联合或不联合假体、单纯乳房假体植入4种方式即刻再造乳房。结果再造手术均取得成功。带蒂TRAM再造47例，LDM再造共42例（其中联合假体28例），单纯乳房假体植入5例。4例出现轻微术后并发症（4．25％）。经过3～67个月随访，局部区域复发率为0，再造乳房形态自然，效果满意，术后外观评价优良率97．87％。结论合理选择病例行保留皮肤或保留乳头乳晕乳腺癌改良根治术后即刻乳房再造是安全可靠的，切口隐蔽并能够保留原有乳房皮肤的感觉，从而获得最佳美容效果，值得广泛推广和应用。     

乳腺癌改良根治术后即刻乳房再造不同方法的临床应用

目的：探讨乳腺癌改良根治术后即刻乳房再造不同方法的适应证、手术方法及优缺点。方法：本组37例乳腺癌患者,分别采用横形腹直肌肌皮瓣带蒂转移、腹壁下动脉穿支皮瓣吻合血管游离移植、背阔肌肌皮瓣带蒂转移、单纯乳房假体置入以及不同方法相结合进行术后即刻乳房再造。结果：除2例单纯TRAM皮瓣患者近腋窝皮瓣局部坏死,1例TRAM＋DIEP联合皮瓣患者下腹正中局部皮瓣脂肪液化外,余34例皮瓣全部成活,形态满意。随访5个月-10年,无腹部薄弱或腹壁疝等并发症,患者生活质量均得到提高。结论：乳腺癌术后即刻再造安全可行,不同的方法各有优缺点,应根据患者具体情况选择适合患者本人的方法进行乳房再造。     

乳腺切除术后全乳再造37例临床研究

目的探讨带血管蒂转移皮瓣在乳腺癌术后乳房再造中的安全性和整形效果。方法2004年3月—2010年6月,对37例乳腺肿瘤患者,行乳房切除术后带蒂背阔肌或TRAM皮瓣乳房再造。其中Ⅰ期再造34例,Ⅱ期再造3例;对其中15例TRAM皮瓣再造的供区下腹部应用涤纶补片加强腹壁。结果1例TRAM皮瓣小部分坏死,6例Ⅰ期再造术后乳房本体皮肤坏死。3例背阔肌皮瓣再造发生背部皮下血清肿;3例TRAM皮瓣下腹中段脂肪液化,无腹壁膨隆或腹壁疝发生。随访2月—72月,1例肿瘤局部复发,1例肝转移。乳房外观评价,总体可接受度94.59％。 结论背阔肌或TRAM带血管蒂转移皮瓣再造是乳房切除术后行全乳再造的有效和安全的方法,应用涤纶补片加强腹壁可以有效预防腹壁软弱和腹壁疝形成。     

乳腺癌改良根治术后即刻乳房再造不同方法的临床应用

目的:探讨乳腺癌改良根治术后即刻乳房再造不同方法的适应证、手术方法及优缺点.方法:本组37例乳腺癌患者,分别采用横形腹直肌肌皮瓣带蒂转移、腹壁下动脉穿支皮瓣吻合血管游离移植、背阔肌肌皮瓣带蒂转移、单纯乳房假体置入以及不同方法相结合进行术后即刻乳房再造.结果:除2例单纯TRAM皮瓣患者近腋窝皮瓣局部坏死,1例TRAM+DIEP联合皮瓣患者下腹正中局部皮瓣脂肪液化外,余34例皮瓣全部成活,形态满意.随访5个月-10年,无腹部薄弱或腹壁疝等并发症,患者生活质量均得到提高.结论:乳腺癌术后即刻再造安全可行,不同的方法各有优缺点,应根据患者具体情况选择适合患者本人的方法进行乳房再造.     

保留皮肤的乳腺癌改良根治术后即时乳房再造15例

目的探讨一种既达到肿瘤根治性切除,又保留乳房美观外形的乳房再造的手术方法。方法对早期乳腺癌,保留乳房皮肤,切除乳腺组织和腋窝淋巴结。应用下腹部横行腹直肌肌皮瓣或扩大背阔肌肌皮瓣即时乳房再造。结果应用下腹部横行腹直肌肌皮瓣乳房再造10例,扩大背阔肌肌皮瓣再造5例。优11例（73．3％）,良4例（26．7％）。结论保留皮肤乳腺癌根治术后即时乳房再造,切口隐蔽,再造乳房形态效果好。对早期乳腺癌患者是一种安全可行的治疗方法。     

乳腺切除术后即刻乳房再造术式的选择

乳腺切除术后即刻乳房再造与二期再造相比在术后效果、患者心理、住院时间以及所需费用等方面均具有明显优势.为乳腺癌术后患者选择一个合适的即刻乳房再造方式十分必要.本文对TRAM皮瓣、双蒂TRAM皮瓣、DIEP皮瓣、背阔肌肌皮瓣、扩张器/假体置入以及背阔肌肌皮瓣联合假体置入等各种即刻乳房再造术式的适应证与禁忌症进行综述.并从肿瘤学角度针对各种乳腺癌根治术如改良根治术、保留乳头、乳晕的乳腺切除术，以及保留皮肤的乳腺切除术、保乳手术后即刻乳房再造等术式的选择策略进行讨论.     

乳腺癌术后乳房重建术式的选择

目的探讨如何选择乳腺癌手术后乳房重建的手术方法及效果分析。方法根据患者乳腺癌手术的具体方法及个体差异，选择转移下腹部横行腹直肌肌皮瓣、背阔肌肌皮瓣、腹壁下动脉穿支游离皮瓣或联合假体乳房重建158例。结果转移下腹部横行腹直肌肌皮瓣乳房重建93例，其中即刻乳房重建65例（满意率为95．38％），延期乳房重建28例（满意率为92．86％）。背阔肌肌皮瓣或联合假体乳房重建59例，满意率为96．61％。腹壁下动脉穿支游离皮瓣乳房重建3例，满意率为100％。假体植入乳房重建3例，满意率为100％。结论乳腺癌手术后选择适当乳房重建的手术方法十分重要；根据个体差异选择不同乳房重建术式，使重建的乳房更加逼真，达到令人满意的效果。     

神经吻合术与乳腺癌术后即刻TRAM皮瓣乳房再造

目的：介绍乳腺癌术后应用下腹横型腹直肌肌皮瓣（TRAM皮瓣）即刻乳房再造的方法，并探讨神经吻合对再造乳房皮肤感觉恢复的疗效。方法：23例乳腺癌患者改良根治术后，Ⅰ期应用单蒂或双蒂横型腹直肌肌皮瓣（TRAM）行乳房再造，单蒂TRAM乳房再造18例，双蒂TRAM乳房再造4例，游离TRAM乳房再造1例，对4例患者进行了神经吻合术，对7例患者进行了血管吻合术。结果：再造手术均取得成功，经过2—72个月随访，无局部复发。行神经吻合的患者再造乳房皮肤感觉较没有行神经吻合者好，患者对再造乳房满意度高。结论：乳腺癌术后Ⅰ期乳房再造能同时满足肿瘤的治疗和形体美容的要求，并且神经吻合术可以一定程度恢复再造乳房皮肤感觉，提高生活质量。     

神经吻合术与乳腺癌术后即刻 TRAM 皮瓣乳房再造

目的：介绍乳腺癌术后应用下腹横型腹直肌肌皮瓣（TRAM皮瓣）即刻乳房再造的方法，并探讨神经吻合对再造乳房皮肤感觉恢复的疗效。方法：23例乳腺癌患者改良根治术后，Ⅰ期应用单蒂或双蒂横型腹直肌肌皮瓣（TRAM）行乳房再造，单蒂TRAM乳房再造18例，双蒂TRAM乳房再造4例，游离TRAM乳房再造1例，对4例患者进行了神经吻合术，对7例患者进行了血管吻合术。结果：再造手术均取得成功，经过2—72个月随访，无局部复发。行神经吻合的患者再造乳房皮肤感觉较没有行神经吻合者好，患者对再造乳房满意度高。结论：乳腺癌术后Ⅰ期乳房再造能同时满足肿瘤的治疗和形体美容的要求，并且神经吻合术可以一定程度恢复再造乳房皮肤感觉，提高生活质量。     

女性乳腺癌保留胸大肌术后Ⅰ期乳房再造

目的：探讨乳腺癌改良根治术同时行上蒂横行腹直肌带蒂肌皮瓣（TRAM）Ⅰ期乳房再造的可行性。方法：行乳腺癌改良根治术Ⅰ期乳房再造7例，其中1例同时行乳头乳晕再造、1例行Ⅱ期乳头乳晕再造。结果：6例患者转移皮瓣全部成活，1例部分皮肤血运欠佳，经二次处理后痊愈。再造乳房术后外观评价：良6例，差1例。结论：此术式既达到了乳腺癌根治的目的又得到了乳房重建的效果，是治疗Ⅰ、Ⅱ期乳腺癌值得推荐的好方法。     

倒T形切口缩乳术在乳房肥大或合并乳腺癌患者中的应用

目的探讨倒T形切口缩乳术在乳房肥大患者，特别是合并乳腺癌的患者手术中的应用及其临床意义。 方法本回顾性研究共纳入2007年10月到2017年10月分别在同济大学附属东方医院及附属同济医院乳腺外科行缩乳术的39例乳房肥大女性患者，均采用倒T形切口(内侧蒂25例，垂直蒂5例，外侧蒂9例)。其中，包括18例符合保留乳房手术指征的乳腺癌患者(内侧蒂10例，垂直蒂4例，外侧蒂4例)。术后6、12个月评价美容效果(乳腺癌患者待放射治疗结束后进行评价)。评估患者的术后并发症、满意度以及复发转移情况。 结果39例患者术后乳房外形自然、对称，明显缩小上提，乳头、乳晕血供和感觉良好，瘢痕不明显，患者满意度高。1例术后2周出现一侧乳房的乳头乳晕区坏死，经过清创换药后愈合。5例术后双侧乳头乳晕感觉减退，其中4例在术后6个月左右恢复正常感觉，1例在术后12个月恢复。5例出现术后局部乳房组织硬结，其中3例为接受过放射治疗的乳腺癌患者，二次手术切除硬结后无再次发生。3例出现瘢痕处猫耳畸形，再次局部麻醉手术修整后效果良好，3例瘢痕增粗，其余患者瘢痕正常。乳腺癌患者中有3例出现放射治疗后患侧乳房皮肤水肿，术后12个月消退。术后6个月进行了美容效果评价，极好25例，良好10例，中等4例，差0例(18例乳腺癌患者中，极好9例，良好6例，中等3例，差0例)。术后12个月的美容效果评价显示：极好25例，良好13例，中等1例，差0例(18例乳腺癌患者中，极好9例，良好8例，中等1例，差0例)。随访时间最长的1例患者(双侧乳房单纯性重度肥大)术后观察了10年，乳房外形无明显变化。全部患者术后随访15～120个月，中位随访61个月，18例乳腺癌患者均无局部复发转移。 结论对于乳房肥大，特别是合并乳腺癌的患者，采用倒T形切口缩乳术，既可切除病变，又可缩小并悬吊乳房。     

Preoperative breast MRI in early-stage breast cancer

Rapid uptake of new imaging technology is a major contributor to rising healthcare costs. Preoperative breast magnetic resonance imaging (MRI) for patients with early-stage breast cancer has dramatically increased in use without the evidence of improved outcomes compared to standard assessment and is associated with higher rates of mastectomy. A decision analytic model was developed to evaluate the impact of adding breast MRI to the preoperative evaluation of women with early-stage breast cancer who were candidates for breast-conserving therapy on patient outcomes measured in quality-adjusted life years (QALYs). Model inputs, including survival, recurrence rates, and health utilities, were obtained from a comprehensive literature review. One-way sensitivity analyses were performed to estimate threshold values for key parameters at which adding MRI would become the optimal imaging strategy over standard assessment. Preoperative MRI resulted in 17.77 QALYs compared to 17.86 QALYs with standard assessment, a decrease of 0.09 QALYs or 34?days. In sensitivity analyses, standard assessment was associated with better patient outcomes than preoperative breast MRI across all plausible probabilities for mastectomy, local recurrence, and health utilities. For routine preoperative breast MRI to become the optimal strategy, the conversion rate to mastectomy after preoperative MRI would need to be <1?% (versus the range of 3.6-33?% reported in the literature). Routine preoperative breast MRI appears to confer no advantage over the standard diagnostic evaluations for early-stage breast cancer and may lead to worse patient outcomes.     

Glycolytic enzymes in breast cancer, benign breast disease and normal breast tissue

The activities of hexokinase, phosphofructokinase, aldolase, enolase and pyruvate kinase were studied in breast cancer tissues, in comparison to benign breast disease and normal breast tissues. The enzyme activities in breast cancer were significantly increased compared to normal and benign breast tissues (p less than 0.001). Also the increase in activity in benign disease compared to normal was statistically significant (p less than 0.001). Within the group of benign diseases, fibroadenomas could be distinguished from fibrocystic disease, the former generally showing higher activities compared to the latter (p less than or equal to 0.05). Carcinoma subgroups, classified according to their histology, could not be recognized enzymologically. In addition, isozyme composition of pyruvate kinase and enolase was studied. We did not find a significant shift towards K type pyruvate kinase expression in benign disease compared to normal breast tissues. Also fibroadenomas did not differ from fibrocystic disease. However, the amount of K type pyruvate kinase in carcinomas proved to be significantly higher in comparison to benign disease and normal breast tissues (p less than 0.001). Expression of alpha gamma-enolase in normal breast tissue was virtually absent. In benign disease only a minority of specimens did show the hybrid alpha gamma-enolase. Nearly all carcinomas had alpha gamma-enolase expression and in 20% of the carcinomas gamma gamma-enolase could be detected (so-called neuron-specific enolase). By discriminant analysis, the function giving the best discrimination compared to the histological data was based on natural logarithm aldolase and the total of gamma-enolase subunits. Contrary to expectation, the regulator enzymes of glycolysis; i.e., hexokinase, phosphofructokinase and pyruvate kinase were not included in this discriminant function. The best fit produced a 90% correct classification in both benign and malignant disease. If these findings are confirmed to a larger series, the discrimination is sufficiently strong to form the basis of a clinically useful tool.     

保乳术和延迟即刻再造术对乳腺癌患者生活质量的影响

目的探讨保乳术和延迟即刻再造术对乳腺癌患者手术后生活质量(QOL)的影响。方法选取2010年1月至2015年6月北京协和医院行保乳术和延迟即刻再造术后于2016年3月至2016年4月在医院乳腺外科门诊随访的64例患者,其中保乳手术30例(保乳组),延迟即刻再造术34例(乳房再造组)。应用肿瘤治疗功能评价系统(FACT-B)量表对两组患者进行生活质量测评比较。结果两组患者生理状况、社会/家庭状况、情感状况、功能状况、总体生活质量评价FACT-G和FACT-B条目状况比较,差异无统计学意义(P>0.05);乳房再造组患者附加关注(乳腺癌特异模块)方面QOL优于保乳术组,差异有统计学意义(29.37±2.72vs 24.05±7.01,P<0.05)。结论乳腺癌保乳术和延迟即刻再造术后患者生活质量无明显差异。     

保留乳房天然结构的乳腺癌改良根治术后即刻乳房成形术的临床应用

目的探讨保留乳房天然结构的乳腺癌改良根治术后即刻自体组织乳房成形术在临床中的运用价值。方法乳腺癌患者12例,其中DCIS 6例,浸润性导管癌3例,小管癌1例,髓样癌1例,黏液癌1例;保留乳房皮肤的乳腺癌改良根治术9例,保留乳头乳晕复合体的乳腺癌改良根治术3例。全组均保留或重建乳房下皱襞,切除乳腺组织和腋窝淋巴结,应用下腹部横行腹直肌肌皮瓣或背阔肌肌皮瓣即刻乳房成形。结果横行腹直肌肌皮瓣乳房成形术3例,背阔肌肌皮瓣乳房成形术9例,术后皮瓣均存活,皮瓣血管通畅,成形乳房外观良好。结论对早期乳腺癌患者行保留乳房天然结构的乳腺癌改良根治术后即刻自体组织乳房成形,切口隐蔽,成形乳房形态效果良好,可以获得较好的美容效果。     

早期乳腺癌部分乳腺加速放疗

随着乳腺癌术后复发模式的研究进展,部分乳腺照射方法 成为乳腺癌放疗的热点.组织间插植、球囊近距离治疗、术中放疗及三维适形放疗和调强放疗等部分乳腺加速放疗已进入临床研究.其局部控制率和安全性与全乳腺照射比较相当,同时具有治疗周期短、方便患者等优势.部分乳腺加速放疗在部分患者有望代替全乳腺放疗,成为早期乳腺癌保乳术后放疗的标准治疗之一.

Abstract：

With a view to patterns of local recurrence after breast conserving surgery, whole breast irradiation(WBI) after surgery is controversial and partial-breast irradiation(PBI) came up. Many clinical trials related with accelerated partial-breast irradiation using a variety of radiotherapeutic techniques such as interstitial brachytherapy (IBT), MammoSite Radiation Therapy System, intraoperative radiotherapy(IORT), threedimensional conformal radiotherapy(3-DCRT)and intensity modulated radiation therapy(IMRT) in selected patients have been carried out. Accelerated partial-breast irradiation that provides faster, more convenient treat-ment demonstrates local control rate and safety comparable to that of whole breast irradiation. Partial breast irradiation may be an alternative way to whole breast radiotherapy and will be one of the standard treatments in women with early breast cancer seeking breast conservation.     

早期乳腺癌保乳手术后加速部分乳腺照射与全乳照射剂量学的比较

目的比较早期乳腺癌患者保乳手术后加速部分乳腺照射(APBI)与全乳照射(WBI)剂量学的差异。方法选取2013年1月至2013年12月间收治的26例保乳术后采用APBI治疗的乳腺癌患者作为观察组,另选取同期保乳术后采用WBI治疗的28例乳腺癌患者作为对照组。采用剂量体积直方图(DVH)比较两组患者剂量学差异,总结两组患者的短期疗效;比较观察组患者在有无图像指导下的位移差异。结果观察组患者的平均剂量(Dmean)、照射体积百分比(V103、V105、V110)和靶区剂量不均匀指数(IHI)均显著低于对照组,各项危及器官(OARS)照射剂量均显著低于对照组,且心脏和肺的照射体积也显著低于对照组,差异均有统计学意义(均P<0.05)。观察组患者美容满意率为96.2%(25/26),对照组患者为67.9%(19/28),两组间差异有统计学意义(P<0.05)。观察组患者在有无图像引导下的位移差异均有统计学意义(均P<0.05)。结论早期乳腺癌患者保乳手术后APBI照射剂量低于WBI,改善靶区剂量分布,降低心肺等组织高剂量受照体积,结合图像引导,可以增加准确性。     

Controversies in breast conservation treatment for breast cancer

Breast conservation treatment has become the standard treatment for early breast cancer patients, after the equivalence of mastectomy and breast conservation treatment was demonstrated in prospective, randomized trials and large retrospective studies. New questions, such as the feasibility of neoadjuvant chemotherapy in improving breast conserving rate, the appropriateness of breast conservation treatment in ductal carcinoma in situ, the effectiveness of radiation therapy in patients treated by breast conservation, and patient selection for breast conservation without radiation, are now being raised. Future work that needs to be done to answer these questions is discussed in this review.     

Prostate specific antigen in breast cancer,benign breast disease and normal breast tissue

Prostate specific antigen (PSA) is a tumor marker used widely for the diagnosis and monitoring of prostatic adenocarcinoma. Recently, we provided evidence that PSA may also be produced by breast tumors. In this report we examined quantitatively the PSA levels in 199 breast tumors, 48 tissues with benign breast disease (BBD, 34 fibroadenomas), and 36 normal breast tissues. Significant amounts of PSA (≥ 0.030 ng of PSA per mg of total protein) were found in 28% of breast tumors, 65% of BBD tissues, and 33% of normal breast tissues. PSA positivity in breast tumors was highest in stage I disease (34%) and decreased with disease stage (24% in stage II and 18% in stage III–IV). Using polymerase chain reaction amplification we have shown PSA mRNA presence in patients with PSA protein-positive tissues (benign and malignant) but not in patients with PSA protein-negative tissues. Our data suggest that PSA is expressed frequently by normal breast tissue, by tissue of benign breast diseases, and by breast cancer tissue. Highest expression is seen in benign breast disease and lowest expression in advanced stage cancerous tissue. As PSA production is mediated by steroid hormones and their receptors, we propose that PSA may be a new marker of steroid hormone action in the normal or diseased female breast. The role of this enzyme in the development of breast diseases including breast cancer is currently unknown.